Skip to main content
BioArctic logo

BioArctic — Investor Relations & Filings

Ticker · BIOA ISIN · SE0010323311 LEI · 549300Y0OI2WVUNHLC33 ST Professional, scientific and technical activities
Open in API
Filings indexed 432 across all filing types
Latest filing 2025-08-29 Regulatory Filings
Country SE Sweden
Listing ST BIOA

About BioArctic

https://www.bioarctic.se/en/

BioArctic is a research-intensive biopharmaceutical company focused on developing disease-modifying treatments, biomarkers, and diagnostics for neurodegenerative diseases. The company's core strategy is based on its proprietary antibody technology, which develops unique treatments that target the misfolded and aggregated proteins considered to be the underlying cause of disorders such as Alzheimer's and Parkinson's disease. Through strategic partnerships with global pharmaceutical companies, BioArctic advances its innovative therapies from research through clinical development and commercialization, aiming to address significant unmet medical needs in neurology.

Recent filings

Filing Released Lang Actions
US FDA approves Leqembi® IQKLIK ™ (lecanemab-irmb) subcutaneous injection for maintenance dosing for the treatment of early Alzheimer’s disease
Regulatory Filings Classification · 1% confidence The document is a press release issued by BioArctic AB regarding the FDA approval of a new subcutaneous injection method for their partner Eisai's drug, Leqembi. It details the regulatory milestone, the clinical implications, and the commercial impact. As it is a corporate announcement regarding a significant business/regulatory event (FDA approval) and does not fit into specific financial reporting categories like 10-K or IR, it is classified as a general regulatory filing/announcement.
2025-08-29 English
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Delårsrapport' (Interim Report) for the period April–June 2025. It contains comprehensive financial statements, including income statements, cash flow data, and key financial ratios (e.g., Nettoomsättning, Rörelseresultat). It also includes a 'Vd har ordet' (CEO statement) and detailed business updates, which are characteristic of a quarterly financial report. It is not an announcement of a report (RPA) as it contains the full financial data and analysis. Q2 2025
2025-08-28 Swedish
Interim / Quarterly Report 2025
Interim / Quarterly Report Classification · 1% confidence The document is explicitly titled 'Interim Report' and covers the period 'April – June 2025'. It contains comprehensive financial statements, including a 'Financial summary', 'Key financial performance indicators', and detailed management commentary on business operations, strategy, and project portfolios. It meets the criteria for an Interim/Quarterly Report (IR) as it provides substantive financial data and analysis for a period shorter than a full fiscal year. Q2 2025
2025-08-28 English
BioArctic och Novartis ingår options-, samarbets- och licensavtal som nyttjar BrainTransporter™ med initial betalning om 30 miljoner USD samt ytterligare potentiella milstolpar och royalties
M&A Activity Classification · 1% confidence The document is a press release from BioArctic AB announcing a new licensing and collaboration agreement with Novartis regarding their BrainTransporter technology. It details the financial terms (initial payment of 30 million USD and potential milestone payments) and the nature of the partnership. This falls under the category of corporate announcements regarding business development, partnerships, and financing/capital-related agreements, which is best classified as a Regulatory Filing (RNS) as it is a standard corporate press release regarding a material event.
2025-08-26 Swedish
BioArctic and Novartis sign an option, collaboration and license agreement using BrainTransporter™ for an upfront payment of USD 30 million plus additional potential milestones and royalties
M&A Activity Classification · 1% confidence The document is a press release announcing a new collaboration and license agreement between BioArctic and Novartis. It details the financial terms (upfront payment and potential milestones) and the nature of the partnership. This falls under M&A Activity (TAR) as it relates to a strategic partnership/licensing deal, which is the standard classification for such corporate development announcements in financial databases.
2025-08-26 English
Sales of Leqembi® totaled 23.1 billion yen in the second quarter 2025
Earnings Release Classification · 1% confidence The document is a press release announcing specific financial highlights (Leqembi sales and resulting royalty revenue) for the second quarter of 2025. It provides key performance metrics ahead of the full quarterly report, which is explicitly stated to be published on a later date (August 28). This fits the definition of an Earnings Release (ER), as it focuses on initial financial highlights rather than being the full report itself. Q2 2025
2025-07-31 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.